A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers

Movement Disorders

Volumn 30, Issue 3, 2015, Pages 393-401

  Sturrock, Aaron ^a,b   Laule, Corree ^c   Wyper, Katy ^c   Milner, Ruth A ^d   Decolongon, Joji ^b   Santos, Rachelle Dar ^b   Coleman, Allison J ^b   Carter, Kimberley ^b   Creighton, Susan ^b   Bechtel, Natalie ^e   Bohlen, Stefan ^e   Reilmann, Ralf ^e,f   Johnson, Hans J ^g   Hayden, Michael R ^a,b   Tabrizi, Sarah J ^h   Mackay, Alex L ^c   Leavitt, Blair R ^a,b  

^a Centre for Molecular Medicine and Therapeutics   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f George Huntington Institute   (Germany)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Huntington's disease; MRI; MRS; Myo inositol (MI); N acetyl aspartate (NAA)

Indexed keywords

BIOLOGICAL MARKER; INOSITOL; N ACETYLASPARTIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; AUTOMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOSIS; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MALE; METABOLITE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUTAMEN; SCORING SYSTEM; SPECTROSCOPY; VOXEL BASED MORPHOMETRY; WHITE MATTER; ANALOGS AND DERIVATIVES; BRAIN; CROSS-SECTIONAL STUDY; METABOLISM; PATHOLOGY; STATISTICS; TIME;

ADULT; ANALYSIS OF VARIANCE; ASPARTIC ACID; BIOMARKERS; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HUNTINGTON DISEASE; INOSITOL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PUTAMEN; STATISTICS AS TOPIC; TIME FACTORS; WHITE MATTER;

EID: 84924598441     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26118     Document Type: Article

References (40)

1. Huntington's Disease Collaborative Research Group. A novel gene. containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
3. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
4. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79:874-880.
5. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010;75:1702-1710.
6. Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 1997;62:27-30.
7. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998;50:1033-1040.
8. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
9. Sánchez-Pernaute R, García-Segura JM, del Barrio Alba A, Viaño J, de Yébenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999;53:806-812.
10. Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005;1031:82-89.
11. Gómez-Ansón B, Alegret M, Muñoz E, Sainz A, Monte GC, Tolosa E. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology 2007;68:906-910.
12. van Oostrom JC, Sijens PE, Roos RA, Leenders KL. 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res 2007;1168:67-71.
13. Ruocco HH, Lopes-Cendes I, Li LM, Cendes F. Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Mov Disord 2007;22:2052-2056.
14. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
15. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
16. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
17. Provencher S, LCModel and LCMGui User's Manual, 2005. Available at: http://S-provencher.com.
18. Magnotta VA, Harris G, Andreasen NC, O'Leary DS, Yuh WT, Heckel D. Structural MR image processing using the BRAINS2 toolbox. Comput Med Imaging Graph 2002;26:251-264.
19. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999;14:326-330.
20. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003;61:141-142.
21. Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005;64:1655-1656.
22. Bender A, Auer DP, Merl T, et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005;252:36-41.
23. Davie CA, Barker GJ, Quinn N, Tofts PS, Miller DH. Proton MRS in Huntington's disease. Lancet 1994;343:1580.
24. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996;11:167-173.
25. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-115.
26. Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-1761.
27. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 2008;4:421-427.
28. Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 2000;74:2108-2119.
29. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979;184:539-546.
30. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
31. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001;8:479-491.
32. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
33. Lee WT, Chang, C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog Neurobiol 2004;72:87-110.
34. Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y. Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels. NMR Biomed 2010;23:196-206.
35. Tattersfield AS, Croon RJ, Liu YW, Kells AP, Faull RL, Connor B. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Neuroscience 2004;127:319-332.
36. Tkac I, Dubinsky JM, Keene CD, Gruetter R, Low WC. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J Neurochem 2007;100:1397-1406.
37. Padowski JM, Weaver KE, Richards TL, et al. Neurochemical correlates of caudate atrophy in Huntington's disease. Mov Disord 2014;29:327-335.
38. Brooks WM, Stidley CA, Petropoulos H, et al. Metabolic and cognitive. response to human traumatic brain injury: a quantitative proton magnetic.resonance study. J Neurotrauma 2000;17:629-640.
39. Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol 2013;260:1901-1906.
40. Bustillo JR. Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues Clin Neurosci 2013;15:329-337.